AstraZeneca Sees SOURCE Tezepelumab Failure In Asthma
Comes After Delay For Roxadustat In The US
The SOURCE failure is a reversal for the novel Amgen-partnered TSLP inhibitor after NAVIGATOR success last month, and comes just days after the US FDA requested more analyses of the pivotal data for the kidney disease anemia therapy roxadustat.
You may also be interested in...
Oncology business unit head David Fredrickson talked to Scrip about Tagrisso’s approval as the first targeted adjuvant treatment for patients who have NSCLC with EGFR mutations.
Biohaven’s investigational glutamate modulator troriluzole did not improve symptoms in patients with mild-to-moderate disease, adding to the list of failures in Alzheimer’s disease, as well as for the product itself.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.